Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Despite expert consensus guidelines, data is scarce on how to switch patients with type 2 diabetes when treatment with glucagon-like peptide 1 (GLP-1) receptor agonists is not effective and whether a switch to semaglutide brings any benefit on glucose and weight control for patients with type 2 diabetes. METHODS: Retrospective cohort analysis of patients with type 2 diabetes who were switched from any GLP-1 agonist in a stable dose to subcutaneously administered semaglutide. Primary endpoint was change of glycated haemoglobin (HbA1c) at 6 months. Secondary endpoints were weight, body mass index (BMI), heart rate, blood pressure and adverse events. RESULTS: ) were included. HbA1c was significantly lower 6 months after switching to semaglutide (7.3%; 56 mmol/l). Median body weight was significantly lower at 3 months (94 kg) and 6 months (93 kg) compared to baseline (98 kg). An equipotential dose switch of semaglutide was used in 61 patients (79%) and a stepwise initiation approach was used in 16 patients (21%). Both treatment regimens improved glucose control and weight. Side effects occurred in 28 patients (36%). CONCLUSION: Switching to semaglutide from established GLP-1 analogue therapy improved HbA1c and body weight. Both equipotential and stepwise dosing initiation appear to be effective and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“GLP-1 agonists are an important cornerstone for the treatment of type 2 diabetes [3] and have been proven to be highly efficacious not only for glucose control but also for weight loss [4, 5].”
BackgroundSorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 1×
“Further, patients who already received GLP-1 analogue treatment may have better tolerated a switch to semaglutide, and furthermore, GLP-1-intolerant patients had already discontinued GLP-1 therapy previously because they could not tolerate their previous GLP-1 analogue—both reasons leading to less frequent side effect…”
ResultAhmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Lingvay, I., Desouza, C. V., Lalic, K. S., Rose, L., Hansen, T., Zacho, J., & Pieber, T. R. (2018) · Diabetes Care · doi:10.2337/dc17-2381 · Cited by 81 · cited 1×
“Additionally, different pharmacodynamic effects given the substantially varying biochemical properties and thereby a different effect on appetite, satiety, gastric emptying and insulin compared to the respective GLP-1 analogues are likely causes for the results observed in this study [11, 14, 15].”
ResultSwitching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74 · cited 3×
“To date, only limited data exist for switching GLP-1 analogue therapy to semaglutide-containing treatment even though practical and expert consensus recommendations based on empirical and parallel or case–control data were recently published [1, 2].”
BackgroundIkushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0677-1 · Cited by 28
Cited by
Yale, J.-F., Bodholdt, U., Catarig, A.-M., Catrina, S., Clark, A., Ekberg, N. R., Erhan, U., Holmes, P., Knudsen, S. T., Liutkus, J., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002619 · Cited by 50
Self-citationRudofsky, G., Catarig, A.-M., Favre, L., Grau, K., Häfliger, S., Thomann, R., & Schultes, B. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108931 · Cited by 46
Self-citationMarzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., & Aimaretti, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01799-2 · Cited by 34
Vilsbøll, T., Lindahl, C. Ø., Nielsen, N. F., & Tikkanen, C. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15031 · Cited by 22
Crabtree, T. S. J., Adamson, K., Reid, H., Barnes, D., Sivappriyan, S., Bickerton, A., Gallen, I. W., Field, B. C. T., Idris, I., Ryder, R. E. J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14701 · Cited by 14
“Diabetes duration, y 11 (6-15) 10 (6-15) 13 (10-16) 12 (8-16) 12 (10-15) 14 (11-17) .”
Metadata
- Authors
- Hepprich, M., Zillig, D., Florian-Reynoso, M. A., Donath, M. Y., & Rudofsky, G.
- Venue
- Diabetes Therapy
- Published
- 2021-02-22
- Volume
- 12
- Issue
- 3
- Pages
- 943-954
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- OpenAlex
- W3132182234
- Cited by
- 18
- References
- 9
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. https://app.cochat.ai/papers/10.1007/s13300-021-01016-y
- The paper
- Hepprich, M., Zillig, D., Florian-Reynoso, M. A., Donath, M. Y., & Rudofsky, G. (2021). Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. Diabetes Therapy. https://doi.org/10.1007/s13300-021-01016-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.